TABLE 2.
Most commonly observed regimens at the time of doxorubicin initiation a .
| Regimen, n (%) | Bolus administration (N = 194) | Continuous infusion (N = 399) | All other patients (N = 1040) |
|---|---|---|---|
| Doxorubicin monotherapy | 170 (87.6) | 82 (20.6) | 184 (17.7) |
| Doxorubicin + ifosfamide | 9 (4.6) | 162 (40.6) | 293 (28.2) |
| Doxorubicin + cisplatin | 2 (1.0) | 23 (5.8) | 63 (6.1) |
| Doxorubicin + dacarbazine | 1 (0.5) | 58 (14.5) | 74 (7.1) |
| Doxorubicin + olaratumab | 5 (2.6) | 14 (3.5) | 104 (10.0) |
| Doxorubicin + cyclophosphamide + vincristine, etoposide + ifosfamide | 2 (1.0) | 0 (0.0) | 74 (7.1) |
| Doxorubicin + docetaxel + gemcitabine | 0 (0.0) | 14 (3.5) | 4 (0.4) |
a
Limited to regimens used by >2% of patients in at least one group.